

**IFPA**

GLOBAL LEADER IN FIGHTING  
PSORIATIC DISEASE

**IFPA org no 802428-5986**

# **Annual Accounts 2021**



# Director's Declaration 2021

Founded in 1971, IFPA is the international federation of psoriatic disease associations. We are the psoriatic disease community. Our members represent over 60 million people living with psoriatic disease. Together, we advocate for progress.

## Purpose of the Federation

IFPA is the global voice dedicated to advancing psoriatic disease policy. IFPA is the trusted convener of psoriatic disease stakeholders across sectors and geographies, partnering to strengthen national and regional capacity and leadership. IFPA works with others to generate and share evidence to inform change that can address unmet needs for people living with psoriatic disease.

- **Legitimacy to represent people living with psoriatic disease:** IFPA is the only organization that brings a unified global voice of people living with psoriatic disease to the global agenda.
- **History and track record in the psoriatic disease community:** IFPA has been unifying the psoriatic disease community and has a proven track record of elevating psoriatic disease onto the global agenda.
- **Independence and integrity:** Decisions are exclusively driven by the needs of the people living with psoriatic disease.

## 2021

### The 50<sup>th</sup> anniversary year for IFPA!

Despite many achievements over the past 50 years, people living with psoriatic disease continue to experience significant unmet needs. IFPA has worked hard to gain political support and recognition for people living with psoriatic disease and has received it.

As a step of turning 50 years, IFPA took the opportunity to reflect upon the needs and gaps in the psoriatic disease field and what the focus should be to continue improving lives of those affected. IFPA developed a new global strategy until 2030 and renewed its vision and mission. IFPA changed name from International Federation of Psoriasis Associations to IFPA and developed a visual identity reflecting the action of the new strategy. A new website and programs came alive to support the federation in reaching its goals.

IFPA decided to create a film to mark the important time in the federation's history and to tie together the historical achievements with the renewal of IFPA's name, visual identity and the new global strategy. The film was shown publicly at the opening session of the 6<sup>th</sup> World Psoriasis and Psoriatic Arthritis Conference in June.

Now, it is time to act and implement. IFPA will advocate for greater psoriatic disease recognition and push for countries to deliver on the recommendations set out in the Global



Report on Psoriasis. As the only global organization uniting people living with psoriatic disease worldwide, IFPA is the global leader in fighting psoriatic disease.

Below follows a description on IFPA's activities and achievements during the year.

## Governance

The General Assembly, consisting of IFPA's full Members, is the highest decision-making body of IFPA. The meeting of the General Assembly is held every three years, with the next to be held in 2022.

The General Assembly elects a Board composed of seven members. The Board governs IFPA in accordance with its objectives and its regulatory and statutory obligations. The Board represented by its President shall have the overall responsibility for ensuring the well-functioning of IFPA and compliance by the organization until a new Board is elected at next General Assembly. An extraordinary meeting of the General Assembly can be convened upon the recommendation of the Board or one-third of the full members.

## Board Meetings

In 2021 the IFPA Board had twelve Board meetings, of which all were virtually conducted.

## Extraordinary General Assembly Meeting 2021

The IFPA Board decided to make a full review of the IFPA Constitution and therefore invited all members to a virtual Extraordinary General Assembly in connection with the Member Meeting. The constitution was updated in accordance with proposed alterations.

## IFPA Strategy 2021-2030

IFPA developed the strategy in close collaboration with its members. The process included gathering information from IFPA Board, Secretariat, and selected members for a broad inclusivity in the process and to set the direction for change. Multiple workshops followed, and to pressure test the outlined strategy, IFPA conducted a survey for its members and different stakeholders.

Five strategic goals were set to inform change toward a future where the updated IFPA vision is fulfilled.

## Vision

A future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities.

## Mission

Unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease.

## Goals

**Ensure global representation:** Boost the voices of everyone living with psoriatic disease, everywhere.



**Lead global advocacy:** Fight for the interests of people affected by psoriatic disease. Demand representation on global health and development agendas.

**Strengthen member capacity:** Strengthen IFPA members. Raise national support for people living with psoriatic disease.

**Share knowledge:** Close the gap between knowledge and action. Trigger breakthroughs for people living with psoriatic disease.

**Unite stakeholders:** Build alliances. Transform global, regional, and national collaboration.

The interrelated goals are equally important and support each other. The strategic goals were further broken down in different activities with performance indicators set for 2024 and for 2030.

In addition to goals, four core values was identified, as well as a number of priority issues, those cross-cutting issues that influence the strategic goals and vary in relevance and importance. The priority issues identified by IFPA, and its stakeholders, very much reflected the issues set out in the WHO Global Report on Psoriasis in 2016. The new strategy was finalized and presented to the members at the member meeting, end of June, and immediately put into use.

## Values

**Person-centered:** Ensure that people living with psoriatic disease are at the heart of everything IFPA does.

**Collaborative:** Work together and openly with members and partners.

**Accountable:** Be responsible for all actions

**Bold:** Have the confidence and courage to lead the global psoriatic disease community.

## Priority issues

**Equal access to treatment, specialists and individualized care:** People living with psoriatic disease require access to appropriate treatment and care, including trained healthcare professionals and medicines. However, inadequate access to healthcare is a challenge in many countries across the world.

**Early diagnosis of psoriatic disease:** People living with psoriatic disease can experience unnecessary suffering, irreversible deformities of the joints and disability due to late diagnosis and lack of appropriate treatment. One standard global guideline to help promote early diagnosis of and appropriate treatment for people living with psoriatic disease.

**Making healthcare providers aware of psoriatic disease:** Lack of adequate training for healthcare practitioners and providers results in low awareness of psoriatic disease. Increased awareness and understanding of psoriatic disease among those responsible for providing care can help facilitate early diagnosis and appropriate treatment.

**Stop stigma:** People with psoriatic disease still experience stigmatization and discrimination. Public misconceptions about psoriasis, for example the myth that it is a contagious disease, result in people with psoriatic disease being excluded from everyday life and foster low self-esteem, depression and even suicidal thoughts.



**Change the perception of psoriatic disease and call for consensus on categorizing**

**severity:** Psoriatic diseases are complex and unpredictable conditions with varied manifestations and associated diseases that affect individuals differently. The misperception that psoriatic disease is a mere skin condition and the lack of consensus on categorizing the severity levels of the condition can lead to inadequate treatment and care.

**Multidisciplinary care:** People living with psoriatic disease require access to multidisciplinary care to identify and manage common comorbidities that already exist or may develop, including cardiovascular and metabolic diseases (such as diabetes) and psychological conditions. Multidisciplinary care teams include primary care physicians, dermatologists, rheumatologists, psychologists, psychiatrists, pediatricians, cardiologists, and endocrinologists.

**Link psoriatic disease and mental health:** Psoriatic disease causes great physical, emotional, and social burdens, all of which may impair an individual's quality of life and be psychologically devastating. Increased awareness and focus on the link between psoriatic disease and mental health can help improve quality of life and wellbeing for people living with psoriatic disease.

**Join forces with family and community:** Psoriatic disease affects relationships at home, school, and work, as well as intimate relationships. Community support, caretakers, and families should be included in the fight against psoriatic disease.

## Secretariat

In July, IFPA moved its office to new premises in central Stockholm, which better suited the organization's needs and requirements. During 2021 the IFPA Secretariat consisted of the:

- Executive Director
- Manager Administration and Events
- Communications Manager
- Scientific Officer
- Program Officer – Advocacy and Policy
- Program Officer – Capacity Development
- Project Developer
- Scientific Coordinator, part-time.

The number of filled full-time staff positions at the Secretariat was 7,15. In addition to above staff positions, IFPA also had an intern focusing on member mapping throughout the year.

## Members

New members were welcomed from Canada, China, Ghana and Montenegro. By end of 2021, IFPA had 59 national member organizations in 55 countries and 3 regional member organizations.



## IFPA Member Meeting 2021

The Member Meeting was held June 29 and brought together 66 patient advocates and psoriatic disease stakeholders from all over the world. This year's meeting was once again held in a virtual format and consisted of four sessions:

- Updates from the secretariat
- Unveiling of IFPA's new strategy and branding
- Interactive discussion with members on IFPA's strategy
- Open forum

The open forum discussion focused on new terminology used in the strategic plan, where IFPA has moved away from 'Psoriasis and Psoriatic Arthritis' and will now use 'Psoriatic disease'. The meeting was ended with a short celebration of IFPA's 50-year anniversary, followed by closing words by IFPA Board President, Hoseah Waweru, where he welcomed members to the 6th IFPA Conference (World Psoriasis and Psoriatic Arthritis Conference) held in the days following the member meeting.

## Member survey

As a federation made up of membership associations, it is important for IFPA to continually gauge the level of satisfaction member associations feel with their membership. Each annual member survey therefore includes questions on how members value their membership, as well as questions on what they appreciate and what they do not currently appreciate about IFPA's work. In IFPA's global strategy, 'Strengthen member capacity' is one of the five main goals. Member satisfaction is crucial to IFPA and by 2024 we set out to have a satisfaction rate of 4+ out of 5. In late 2021 as a follow-up on the survey, IFPA Members were also invited to participate in individual calls with IFPA staff, providing opportunity to discuss feedback and suggestions more extensively.

Results of the survey:

- A vast majority (87%) of IFPA Members rated the value of their IFPA Membership as Very Good or Excellent.

Top reasons for being an IFPA Member:

- Support global advocacy efforts
- World Psoriasis Day Campaigns
- Connect with other IFPA Members

More details from the member survey can be found in the ["IFPA Member Survey 2021"](#) report.

## Solidarity Fund

The IFPA Solidarity Fund was created to address the funding gap faced by many of IFPA's members, by awarding grants to support advocacy, education and awareness-raising in psoriatic disease.

During the Solidarity Fund 2021 application call, IFPA received many impressive project applications. From these, IFPA was able to select six projects to receive funding.



- South Africa – Virtual mental health sessions
- Japan – Psoriasis handbook
- Peru – Illustrations for awareness
- Hong Kong – Psoriasis patient survey
- Norway – Community gingerbread baking
- Vietnam – Psoriasis podcast

## Webinars

Designed for the psoriatic disease community, IFPA's webinar series provided updates on research, deep dives into life with psoriatic disease, and advocacy achievements. IFPA Webinars were open live for everyone, and on demand for our members through the IFPA Member Website.

- Research updates: The future of psoriasis – International Psoriasis Council
- Psoriasis, Covid-19 and Vaccinations - PsoProtect
- World Psoriasis Day: A look into the UNITED campaign – IFPA
- European Psoriasis Treatment Guidelines – EuroGuiDerm
- Uniting for Action: WPD 2021 – IFPA
- Generalized Pustular Psoriasis – GPP Specialist Doctor and Patient Experience

## Member Portal

In October, IFPA launched the new IFPA website. Part of the website only accessible for IFPA Members. With the Member Portal, IFPA created a resource to meet the members' needs that is:

- A knowledge hub hosting the latest psoriatic disease research
- A collaborative space for communication between members
- A learning center to continue building capacity and skills
- A place to showcase national work
- A library of resources

## IFPA Accelerator Program

The planning and initiation of the IFPA Accelerator Program started during 2021. The program is one of four flagship programs identified during the process of building a new long-term strategy for IFPA.

The IFPA Accelerator Program was developed as an extension of IFPA's already existing Mentoring Program and Peer Coaching Program. The program aims to:

- Accelerate the growth of IFPA
- Leverage the skills and capacities of selected member associations in each region
- Strengthen regional alliances and facilitate best practice sharing within regions



# Communications

## Rebranding

In connection with IFPA's 50<sup>th</sup> anniversary, the organization needed renewal. IFPA was ready to adopt a new name, visual identity and website that would take the organization into the future together with the new strategy.

### Name

Early in the process, decision was made to choose the abbreviation IFPA as the new name with addition of a tagline to the logotype to take proud ownership of IFPA's role and position in the world. The name IFPA has established itself and is widely known and referred to in the psoriatic field.

### Logo

The new logo stayed with the globe, but a globe that was modernized to visually express a powerful patient organization. The colors, orange and purple, are widely associated with psoriatic disease and are found in the traditional orchid and orange ribbon.

### Visual identity

The dynamic globe in the new visual identity expresses how IFPA creates a powerful force by uniting the collaboration of the many individual parts of this community – its member organizations and partners. At the same time, it resembles the visual part of the disease by expressing both the inflammation and the fight against it. Being the key visual in the new IFPA logo, the globe provides identity and stand out effect as a graphical layer. It also serves as a visual graphical expression that is used on portrait photographs. This provides IFPA with a unique and emotional visual language that puts focus on people living with psoriatic disease.

### Website

The new website is a modern website, with all the necessary functions and most importantly with a well-developed member portal. It includes explanation of all IFPA's program and projects and an interactive page for World Psoriasis Day activities. Furthermore, the website has a section for resources and tools, that will continue grow and close the gap between knowledge and action. In 2021, IFPA was also able to share the data from the study Psoriasis and Beyond on the website.

## Communication channels

### IFPA Update and Newsletters

IFPA continued with the IFPA update, an internal newsletter to communicate more frequently with IFPA members and keep them informed of developing projects and opportunities.

IFPA sent four Quarterly Newsletters to members, stakeholders, and partners. These illuminated such topics as information about the IFPA renewal process, IFPA Conference (6<sup>th</sup> WPPAC), GPA, new strategic action plan for the Coalition, Solidarity Fund, PsoProtectMe, IFPA Webinars, IFPA Ambassadors, World Psoriasis Day, Accelerator Program and other actions in 2021.

## Website

IFPA's website in numbers 2021 (2020):

- Users: 49,141 (25,726)
- Page views: 94,029 (63,344)
- Top four countries frequenting the IFPA website:
  - India 19.9% (USA)
  - USA 17.9% (India)
  - UK 6.4% (Indonesia)
  - Indonesia 5.73% (UK)
- Top five webpages visited:
  - Homepage: 17,804 (12,079)
  - COVID-19 Vaccines and Psoriatic Disease article: 13,604
  - World Psoriasis Day: 9,182 (8,227)
  - Our Cause: 2,503 (3,652)
  - Members: 1,918 (2,578)

## Social media

In September IFPA decided to try two new social media platforms to reach a new audience: TikTok and Clubhouse.

Top post on Facebook was a post advertising the Psoriasis and Beyond Survey at the IFPA Conference, with 2096 reactions.

By the end of 2021 we had this many followers on each account (2020):

1.6K Instagram (1.1K)

430 LinkedIn (158)

6.9K Twitter (6.5K)

14K Facebook (14K)

## Press release tool

Ahead of World Psoriasis Day, IFPA made a global press release. Later in the year a global press release service agreement for 2022 was signed.

## World Psoriasis Day

World Psoriasis Day (WPD) is the annual day dedicated to people living with psoriatic disease. WPD is celebrated on October 29, with the overall aim of:

- Raising awareness about the severity of the disease and the everyday challenges faced by people living with psoriatic disease
- Spreading information about psoriatic disease, refuting common misconceptions and increasing knowledge among people living with the condition
- Improving access to treatment by targeting health ministers, governments and decision-makers
- Creating a united platform to empower people living with psoriatic disease



World Psoriasis Day provides a unique opportunity for IFPA to take action, drive advocacy, and demonstrate leadership among multiple stakeholder groups. IFPA uses World Psoriasis Day to mobilize enthusiasm for a shared theme and goal.

The theme of 2021 was UNITED, the final year in the three-year campaign (Connected, Informed, United). 72 countries participated in the campaign organizing free clinics, social media campaigns, trainings, monument lightings, and more. Worldwide activities were collected on a global map. Allies and advocates joined together. A global petition was launched to raise awareness and demand progress. The result and impact of the campaign is captured in the report "[World Psoriasis Day 2021](#)".

## Now Act Petition

Ahead of World Psoriasis Day, IFPA launched the Now Act Petition. The petition, part of IFPA's advocacy work, calls for action from the countries around the world to implement the WHO recommendations, since much is still left to be done more than 5 years after the community milestones in 2014, UN Resolution on Psoriasis, and in 2016, WHO Global Report on Psoriasis.

The psoriatic disease community united in the petition to demand following actions:

- Change the perception of psoriatic disease
- Ensure equal access to medicines
- Stop stigma
- Advance holistic care
- Prepare the health workforce

The petition will be live until the UN High-Level Meeting on Noncommunicable Diseases in 2025. [Sign the petition here.](#)

## Advocacy and Policy

### IFPA Coalition

In connection with the development of a new IFPA Strategy and re-branding, IFPA also decided to restructure the Global Psoriasis Coalition and re-name it IFPA Coalition. This to make it clear that IFPA is the advocacy body, and the Coalition is the collaborative space gathering and uniting representatives from medical societies, NGOs, the corporate sector, foundations and professional societies. By collaborating across borders, sectors and disease areas, IFPA uses the Coalition to generate support to implement the recommendations outlined in the World Health Organization's 2016 Report on Psoriasis. To reach its goal to lead the global advocacy, IFPA has defined a triple A (AAA) Action plan: Act, Amplify, and Align. The Coalition convened four times in 2021: March, July, September and December. 2021 began with the development of a new three-year strategic action plan for the Coalition, closely connected to IFPA's new global strategy. The Psoriatic Disease Response Index, a resource produced by the Coalition, was presented at the 6<sup>th</sup> World Psoriasis and Psoriatic Arthritis Conference (WPPAC).

## Reports

IFPA developed and launched two advocacy reports:

- **Inside Psoriatic Disease: Diabetes, April 22, 2021**  
In connection with the centenary of the discovery of insulin, IFPA produced a report on psoriatic disease and diabetes, available in English and Spanish. A checklist with tips on prevention and control of diabetes for people living with psoriatic disease was published together with the report. The checklist was made publicly available on the IFPA website in English, Spanish, Arabic, French, Portuguese (Brazil), Portuguese (Portugal), German, Russian, Simplified Chinese, Traditional Chinese and Japanese. The webpage including the report and the checklist received over 900 views by December 31, 2021.
- **Telemedicine for Psoriatic Disease Care, December 12, 2021**  
The report provided context on the current state of virtual care, with emphasis on how Covid-19 has accelerated telemedicine. Moreover, it illustrated benefits and pitfalls of virtual care, collected case studies and provided recommendations to ensure excellent care of people living with psoriatic disease. The report was presented at the Skin & Digital Summit on December 11, a virtual summit with more than 1600 registered attendees from 60 countries.

## Relationship with international policy bodies

IFPA representatives participated in the official delegation of the Global Health Council to the 74th World Health Assembly. An article reporting key learnings from the Assembly was shared with the IFPA membership. IFPA, as an organization in consultative status with the Economic and Social Council (ECOSOC) of the United Nations, submitted a statement highlighting the impact of the COVID-19 pandemic on people living with psoriatic disease. This was part of the official procedures of the ECOSOC high-level segment on the impact of the COVID-19 pandemic on the 2030 Agenda for Sustainable Development organized in the month of July.

IFPA started the pursuit of establishing official relationships with the World Health Organization (WHO). In connection with World Psoriasis Day, IFPA organized a call with a representative of the WHO's department for noncommunicable diseases. During the meeting, IFPA presented the organization and discussed the first steps to engage actively with WHO.

## IFPA's network in advocacy

IFPA renewed its collaboration with the NCD Alliance, the International Alliance of Patients' Organizations (IAPO), the Global Health Council, the International Alliance of Dermatology Patient Organizations (IADPO/GlobalSkin). IFPA is also a member of the Civil Society Engagement Mechanism for Universal Health Coverage (CSEM). IFPA is an active member of the Inclusive Agenda program of the NCD Alliance, a project promoting inclusivity in the non-communicable disease sphere.

In connection with the release of the report "Inside psoriatic disease: diabetes", IFPA published a blog post on Diabetes Voice, the official blog of the International Diabetes



Federation (1800 views by December 31, 2021) and a blog post in the official blog of the British Skin Foundation.

## IFPA Forum

The IFPA Forum is a new program of IFPA designed to put the needs of people living with psoriatic disease at the center of the policy discourse at the regional level. This new program is part of the IFPA Strategy 2021-2030 and will be held for the first time in 2022. In 2021, IFPA worked to concretize the concept of the Forum from the IFPA Strategy in a concept note, approved by the board of IFPA. The concept note was then presented to IFPA members residing in the European region (intended as WHO/Europe, region chosen to host the first IFPA Forum) and to IFPA sponsors. IFPA members residing in the European region were involved in suggesting the topics that will be discussed at the first IFPA Forum in a meeting held in December 2021 and were invited to express their interest in participating in a special taskforce in charge of aiding IFPA with proceedings regarding the Forum. Europso, IFPA's regional member in Europe agreed to partner with IFPA on the Forum and participate in the planning as well as leading the implementation of the roadmap and action plan developed at the Forum.

## Science

2021 was a hectic year at IFPA from a Science point of view. It contained IFPA's own conference, multiple external events, extended collaborations and partnering as well as a shift in wording. IFPA adopted the term "psoriatic disease" to reflect the representation of all people living with the disease. More than "psoriasis" or "psoriatic arthritis," the term psoriatic disease captures the full experience of living with this complex illness, its comorbidities, and all the emotional, social, and financial burdens that come with it.

## IFPA Conference

The 6th World Psoriasis and Psoriatic Arthritis Conference 2021 and IFPA's first fully virtual conference took place June 30 to July 3; the conference is held once every three years and hosted by the IFPA. As part of the new global strategy and visual identity, IFPA decided to change name of the World Psoriasis and Psoriatic Arthritis Conference. Starting next conference in 2024, the name is 'IFPA Conference'.

The Conference's theme was: CONNECTED, INFORMED and UNITED to improve multidisciplinary care for people living with psoriasis and psoriatic arthritis. It was open to the public and had over 800 pre-registered participants from over 65 countries across the globe. The conference attending delegates had access to various sessions, including a scientific and complementary program line-up developed by the scientific committee -including dermatologists, rheumatology experts, and IFPA members. The Conference was accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and designated 15 CME credits. Partners and sponsors hosted symposium satellite sessions. President of the conference was Prof. Dr Med Ulrich Mrowietz from Germany.

To acknowledge the contribution in research, IFPA offered several e-poster awards in different categories to celebrate IFPA's 50th anniversary and partnered with the prestigious peer-reviewed Nature Reviews Rheumatology Journal to offer an additional poster prize selected by the journal. The e-poster awards will be included in future conferences.

At the closing ceremony, IFPA also recognized individuals who contributed invaluable to increasing understanding of psoriatic disease and advocacy over the past five decades.

## External science events

### **GPP virtual Patient Summit, February 26-27**

A global patient organization summit, organized by Boehringer Ingelheim in collaboration with representatives of the patient community. The aim of the summit was to jointly create value for patients. Summit concept and topics were co-created with a group of patient representatives across the world and included awareness, innovation, collaboration, COVID-19, communication, accessibility and digital health. IFPA moderated in two workshops and provided valuable insights on the topic “Access to Conferences; The World Psoriasis and Psoriatic Arthritis Conference”; a paradigm for other patient organization led congresses.

### **EULAR virtual, June 2-5**

The European League Against Rheumatism (EULAR) Congress was held as an online event. IFPA followed the virtual sessions live, receiving the latest updates on new treatment options for psoriatic arthritis. In addition, sessions addressed the risk of comorbidities like cardiovascular disease, diabetes, and metabolic syndrome among others.

### **GlobalSkin Virtual Conference, June 3**

GlobalSkin brought together over 91 dermatology patient group leaders and dermatology stakeholders from all regions of the world for a virtual half-day Conference named Thrive 2021. The event was designed to strengthen connections and provide opportunities to collaborate and network. IFPA was represented at the meeting and showcased its work in a virtual booth.

### **GRAPPA Annual Meeting virtual, July 8-10**

Although no IFPA representative was able to attend the GRAPPA (Group for Research and Assessment of Psoriatic Arthritis) Annual Meeting, a joint IFPA/GRAPPA session were held at the 6<sup>th</sup> WPPAC a few days ahead of the GRAPPA annual meeting. This collaborative session featured patient testimonials followed by lectures from GRAPPA on the particular features, challenges, and recent research on palmoplantar pustulosis (PPP).

### **APLAR virtual, August 28-31**

The 28th Asia-Pacific League of Associations for Rheumatology Congress was held virtually and had various topics including treatment options and care for people living with Psoriatic Arthritis and Axial SpA. The GRAPPA team presented the updated recommendations for the treatment of psoriatic arthritis.

### **ESDR virtual, September 22-25**

Being the 50<sup>th</sup> annual meeting, content reflected on the history of the ESDR with five ESDR anniversary lectures. The virtual meeting warmly welcomed IFPA and other patient organizations in multiple workshops and satellite meetings with special interest groups engaging on psoriasis, eczema and the skin barrier. IFPA presented its annual work activities and promote awareness on psoriatic disease in a virtual booth.

### **EADV virtual, September 29-October 2**

It was the 30<sup>th</sup> anniversary edition of the European Academy of Dermatology and Venereology Congress, showcasing the latest innovations in dermatology and venereology and providing a platform for deep scientific exchange within the dermato-venereology

community. The congress also celebrated the unique achievements and important milestones of both the Academy and Congress over the past 30 years.

IFPA's scientific officer represented IFPA in one of the satellite symposiums. The lecture was entitled United: Bridging the GaPP. A panel of experts, including IFPA, shared new insights about Generalized Pustular Psoriasis (GPP), recent findings on patient perceptions of rare diseases and IFPA's call to action for timely access to multidisciplinary care. IFPA also had a virtual booth to bring attention to World Psoriasis Day, the Now Act petition and IFPA's cause.

### **IDEOM virtual, November 19-20**

IDEOM's (International Dermatology Outcome Measures) key stakeholders include physicians, industries, insurers, government representatives, and patient research partners within multiple workgroups in the dermatologic areas. IFPA attended the annual meeting together with, among others, IFPA member associations represented by EUROPSO, Epidermia Greece, Psoriasisforeningen Denmark, and National Psoriasis Foundation, USA.

## **The Global Psoriasis Atlas (GPA)**

The Global Psoriasis Atlas is an international project launched in 2016 by IFPA, International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). It has made incredible progress and is delivered by global experts and an academic project team led by the University of Manchester. The vision is that the GPA will become the leading epidemiological resource globally on psoriasis and psoriatic arthritis providing the common benchmark on the burden of psoriasis in all countries and regions throughout the world. The Atlas will seek to: drive continuous improvement in understanding the natural history of psoriasis; uncover how it affects the individual and society; understand how healthcare can be improved for those living with the disease.

The GPA website is the first-ever comprehensive online epidemiological resource database tool. It contains data on the number of psoriasis cases, healthcare data and looks in depth at the experiences and faces behind people living with psoriasis.

In 2021:

- GPA made its website available in Spanish language
- studies were completed into prevalence, incidence and mortality in Taiwan and Chile
- epidemiological research was conducted in Malaysia
- the global IRASPEN registry investigated the natural course of pustular psoriasis, disease burden therapeutics and genetics
- coordinators recruited for the global IRASPEN registry in Switzerland, Brazil and Singapore

October 13, ILDS hosted a virtual global webinar. The event was a chance to learn more about the collaboration between ILDS, IFPA and IPC on the GPA model with the title: Bringing data to life.

IFPA's Scientific Officer presented the involvement of IFPA and global member associations in the GPA as well as the important role of the GPA in supporting IFPA's national, regional and global advocacy efforts.

Further information is available on [www.globalpsoriasisatlas.org](http://www.globalpsoriasisatlas.org).

## PsoProtect & PsoProtectMe

In 2021, IFPA continued its partnering with PsoProtect, a global registry collecting de-identified data from health care professionals caring for patients with psoriasis and COVID-19. There is also a registry for self-reported data by patients through PsoProtectMe. By collecting data, the team at PsoProtect can analyze many facets of the pandemic's impact, including outcomes of COVID-19 in people who have psoriasis, the mental health burden of living through the pandemic, and psoriasis flares because of stress or reduced access to treatment.

2021 in numbers:

- 5 publications detailing the burden of COVID-19
- 4791 cases reported to PsoProtectMe
- 1272 cases reported to PsoProtect

The results are not only important for scientific reasons. IFPA and other organizations will also be able to use these results to advocate for better provisions for people living with psoriatic disease through this pandemic and in future crises.

## Psoriasis and Beyond

Psoriasis and Beyond is a joint research initiative between IFPA, 16 national psoriasis organizations and Novartis Pharma AG. The study is overseen by a Steering Committee of patient advocates, dermatologists and rheumatologists.

By understanding the patient experience, including patient awareness of their own disease, our community will be better equipped to design meaningful interventions. The results of the study are hosted on IFPA's website for easy access to patient advocates.

Two sets of data were published in 2021 and more publications will follow:

- At 6<sup>th</sup> WPPAC in June - Psoriasis and Beyond designed to capture people's understanding of psoriatic disease and the emotional and physical burden – interim results abstract
- At Fall Clinical Dermatology Conference in October - A closer look at patients' perspective on Psoriatic Disease Burden – abstract

## Psoriatic disease and women

The recent survey from IFPA, EUROPSO, and UCB interviewing women from 11 European countries living with moderate-to-severe psoriatic disease was published in the International Women's Journal of Dermatology in December 2021. The findings provide meaningful insight into the experience of women living with psoriatic disease.

## European Treatment Guidelines for Psoriasis

Treatment guidelines are an essential tool to improve quality of care for people with psoriasis. Many countries lack specific guidelines or protocols on the care and management of psoriasis. In 2020, representatives from IFPA were invited to participate in the consensus meetings for the European Centre for Guidelines Development led by the European



Dermatological Forum. In collaboration and support from the Dermatology experts, a patient guide was developed to introduce patients to the new guideline on systemic treatment of psoriasis vulgaris - part 1, published in July 2020. A patient checklist was published alongside the guidelines.

During 2021, IFPA was consulted on the part 2 of the European Dermatology Guideline to be published in November. Patient representatives input and consensus was included in the final publication, which provides guidance for specific comorbidities – such as psoriatic arthritis and depression. It holds recommendations for treatment of people with chronic plaque psoriasis and diabetes, neurological disease and infectious diseases. These publications have been made available to open access and published by the Journal of the European Academy of Dermatology and Venereology (JEADV).

IFPA is working to adapt the guideline for use in other local contexts outside of Europe.

## Projects 2021

### IFPA's Psoriatic Disease Ambassadors

IFPA has often received requests to contribute patient testimonials, survey participants, and stars for photo and video assets. Unfortunately, IFPA often struggled to find participants available, with thoughtful messaging, representing the full spectrum of people living with psoriatic disease and their caregivers in terms of race, age, body type, gender, and severity of disease.

Through the Ambassador Training program, initiated in 2021, IFPA recruited a group of 16 pilot ambassadors and gave them training on advocacy messaging. This is the beginning of building a larger network of candidates to participate in internal and external communications projects. The program will continue to grow for years to come, with the aim to unite a team of skilled ambassadors, reliable and ready to join forces with IFPA. They will speak up for psoriatic disease and its comorbidities in the global arena. Their expert perspectives will boost the diverse needs and experiences of people living with psoriatic disease, everywhere.

### IFPA Island

IFPA built an island in the Nintendo Switch's Animal Crossing: New Horizons (ACNH) game. It is a family-friendly bestselling game where players are transported to the virtual island, gather material to craft items used to decorate the island attributable to psoriatic disease. Other ACNH players can visit the island and interact with its creator.

IFPA is the first patient organization to use this tool, with the purpose to increase knowledge and interact with the younger population of people living with psoriatic disease.

Up to half of people with psoriatic disease develop it as children or young adults. IFPA Island is a safe space for everyone, especially people living with psoriatic disease, to interact and have fun together. Everyone is invited to visit the island, take and share pictures in the psoriatic disease-themed spaces, participate to events, and learn more about psoriatic disease. Joel Nelson – one of IFPA's ambassadors and owner of the Twitch channel JoelvsArthritis – livestreams and shares his story with psoriatic-associated Juvenile Idiopathic Arthritis while creating the IFPA Island.



## Corporate Partners

As part of the IFPA Partnership Program, IFPA received support from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, LEO Pharma, Lilly, Novartis, Pfizer and UCB.

Separate support for the IFPA Coalition was provided by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, LEO Pharma, Lilly, Novartis, and UCB.

Separate support for World Psoriasis Day was provided by Almirall and Janssen.

For the IFPA Conference support was provided as follows:

<b>Package</b>	<b>Company</b>
Diamond	Janssen
Platinum	Boehringer Ingelheim
Platinum	Lilly
Gold	Amgen
Gold	Pfizer
Gold	UCB
Silver	AbbVie
Silver	Bristol-Myers Squibb
Bronze	Leo Pharma
Bronze	Novartis

IFPA has also collaborated separately with numerous corporate partners in various projects and initiatives within science and advocacy to improve the lives of all people affected by psoriatic disease. Project sponsors are revealed under the project description on IFPA’s website.



# Administration report

The Board of IFPA hereby delivers the annual accounts for the year 2021-01-01 to 2021-12-31.

Regarding the result and financial positions, please refer to the attached statements.



**President**  
Hoseah Waweru, M.D.  
Nairobi, Kenya



**Vice President**  
Ingvar Ágúst Ingvarsson  
Reykjavik, Iceland



**Secretary**  
Leticia Lopez  
San Juan, Puerto Rico



**Treasurer**  
Josef de Guzman  
Manila, Philippines



**Board Member**  
Kathleen Gallant  
Pittsburgh, USA



**Board Member**  
Silvia Fernandez Barrio  
Buenos Aires, Argentina



**Board Member**  
David Trigos Herraes  
Oviedo, Spain



# IFPA

## Org no 802428-5986

### Profit and loss account

	2021-01-01 2021-12-31		2020-01-01 2020-12-31	
<b>Income</b>	SEK	EUR 10,2269	SEK	EUR 10,0375
Membership fees	73 122	7 285	108 463	10 806
Rounding- off to whole kronor	2	0	2	0
WPPAC	4 154 082	413 856	0	0
Abbvie	929 183	92 571	430 475	42 887
Almirall S.A.	99 254	9 888	0	0
Amgen	1 033 491	102 963	444 527	44 287
Boehringer Ingelheim	1 826 026	181 920	782 408	77 949
Bristol-Myers Squibb	1 044 297	104 040	1 199 182	119 470
Celgene	0	0	97 333	9 697
Eli Lilly	787 054	78 411	546 951	54 491
Janssen	101 590	10 121	1 311 971	130 707
LEO Pharma A/S	1 039 857	103 597	602 358	60 011
Novartis	1 073 749	106 974	980 383	97 672
Pfizer	707 847	70 520	702 625	70 000
UCB	1 858 333	185 139	689 032	68 646
Other operating income	7 773	774	0	0
<b>Total income</b>	<b>14 735 659</b>	<b>1 468 061</b>	<b>7 895 708</b>	<b>786 621</b>

## Profit and loss account

	2021-01-01 2021-12-31	2020-01-01 2020-12-31		
Costs	SEK	EUR 10,2269	SEK	EUR 10,0375
Outgoing donations	-120 304	-11 985	0	0
Translations	-79 618	-7 932	0	0
Office rental agreement	-426 220	-42 463	-559 879	-55 779
Software programs	-89 874	-8 954	-63 518	0
Freight and transport	-21 942	-2 186	-18 707	-1 864
Conference costs	-21 304	-2 122	-338 758	-33 749
Travel costs	18 883	1 881	-167 855	-16 723
Refund members	0	0	-36 984	-3 685
Hotel costs	-5 820	-580	-31 989	-3 187
Food	-302	-30	-6 385	-636
Reimbursement	0	0	-34 532	-3 440
Printing costs	-4 463	-445	-43 060	-4 290
PR-Marketing	-658 982	-65 652	-38 405	-3 826
Newsservice, PR	-72 675	-7 240	-20 625	-2 055
Entertainment	-53	-5	-2 205	-220
Gifts	-11 823	-1 178	0	0
Office material	-73 220	-7 295	-85 102	-8 478
Phone	-46 534	-4 636	-64 780	-6 454
Insurance for the organization	-15 125	-1 507	-14 612	-1 456
Honorariums for external	-32 946	-3 282	0	0
Accountant and audit	-118 101	-11 766	-353 297	-35 198
Consultants	-2 495 139	-248 582	-3 167 293	-315 546
Web	-7 155	-713	-7 823	-779
IT-costs	-57 141	-5 693	-109 362	-10 895
Bank fees	-9 319	-928	-9 945	-991
Membership fees	-218 315	-21 750	-267 163	-26 617
Subscriptions and articles	0	0	0	0
Other operating expenses	-630 735	-62 838	156 699	15 611
Staff costs	-5 319 453	-529 958	-5 054 079	-503 520
Interest taxes and fees	-1 644	-164	-1 027	-102
Exchange profit/loss	-88 772	-8 844	-95 893	-9 553
<b>Total costs</b>	<b>-10 608 098</b>	<b>-1 056 847</b>	<b>-10 436 580</b>	<b>-1 033 431</b>
<b>Profit (+) / Loss (-)</b>	<b>4 127 562</b>	<b>411 214</b>	<b>-2 540 872</b>	<b>-246 810</b>

**Costs per activity**2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
<b>20. Income</b>				
Bank fees	-1 244	-124	0	0
Exchange profit/loss	-47 273	-4 710	-72 542	-7 227
<b>Total costs</b>	<b>-48 518</b>	<b>-4 834</b>	<b>-72 542</b>	<b>-7 227</b>

<b>30. Governance</b>				
Software Programs	-1 941	-193	-2 340	-233
Freight and transport	-7 603	-757	0	0
Conference costs	0	0	-380	-38
Travel costs	0	0	-75 593	-7 531
Hotel costs	0	0	-26 750	-2 665
Food	0	0	-6 248	-622
Reimbursement	0	0	-23 661	-2 357
Phone	-2 033	-203	-2 332	-232
Insurance for the organization	-7 500	-747	-7 500	-747
Membership fees	-9 807	-977	-17 168	-1 710
Staff costs	-5 586	-557	0	0
Exchange profit/ loss	-427	-43	0	0
<b>Total costs</b>	<b>-34 898</b>	<b>-3 477</b>	<b>-161 972</b>	<b>-16 137</b>

<b>40. Members</b>				
Outgoing donations	-120 304	-11 985	0	0
Software programs	-1 828	-182	0	0
Freight and transport	-989	-99	0	0
Conference costs	0	0	-217 202	-21 639
Travel costs	0	0	-42 303	-4 214
Refund members	0	0	-36 984	-3 685
Reimbursement	0	0	-5 902	-588
Gifts	-798	-80	0	0
Consultants	0	0	-16 250	-1 619
IT-costs	-688	-69	0	0
Staff costs	-815 860	-81 281	0	0
<b>Total costs</b>	<b>-940 467</b>	<b>-93 695</b>	<b>-318 555</b>	<b>-31 737</b>



**Costs per activity**2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
<b>45. Accelerator</b>				
Other operating expenses	-41 875	-4 172	0	0
<b>Total costs</b>	<b>-41 875</b>	<b>-4 172</b>	<b>0</b>	<b>0</b>

<b>50. Secretariat and Staff</b>				
Office rental agreement	-426 220	-42 463	-559 879	-55 779
Software programs	-62 570	-6 234	-36 638	0
Freight and transport	-859	-86	-2 623	-261
Conference costs	0	0	-11 598	-1 156
Travel costs	25 560	2 546	-4 922	-490
Hotel costs	-2 800	-279	0	0
Food	0	0	-137	-14
Printing costs	-3 869	-385	0	0
Entertainment	0	0	-2 205	-220
Office material	-43 924	-4 376	-85 102	-8 478
Phone	-44 501	-4 433	-62 448	-6 221
Insurance for the organization	-7 625	-760	-7 112	-709
Accountant and audit	-118 101	-11 766	-353 297	-35 198
Consultants	-14 519	-1 446	-314 800	-31 362
Web	-366	-36	0	0
IT-costs	-56 453	-5 624	-109 362	-10 895
Bank fees	-8 075	-804	-9 945	-991
Interest taxes and fees	-1 644	-164	-1 027	-102
Staff costs	-1 828 000	-182 117	-5 054 079	-503 520
Exchange profit/loss	-488	-49	-672	-67
<b>Total costs</b>	<b>-2 594 455</b>	<b>-258 476</b>	<b>-6 615 847</b>	<b>-659 113</b>

<b>60. Communication</b>				
Software programs	-22 668	-2 258	-24 540	-2 445
PR-Marketing	-165 420	-16 480	-3 778	-376
Newsservice, PR	-1 984	-198	-20 625	-2 055
Office material	-22 867	-2 278	0	0
Web	-4 174	-416	-7 823	-779
Staff costs	-433 600	-43 198	0	0
<b>Total costs</b>	<b>-650 713</b>	<b>-64 828</b>	<b>-56 766</b>	<b>-5 655</b>

**Costs per activity**2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
<b>65. World Psoriasis Day</b>				
Translations	-54 737	-5 453	0	0
Freight and transport	0	0	-16 084	-1 602
Printing costs	0	0	-43 060	-4 290
PR-Marketing	-290 064	-28 898	-16 788	-1 673
Newsservice, PR	-69 038	-6 878	0	0
Consultants	0	0	-3 130	-312
Staff costs	-372 999	-37 161	0	0
Exchange profit/loss	0	0	2 244	224
<b>Total costs</b>	<b>-786 838</b>	<b>-78 390</b>	<b>-76 818</b>	<b>-7 653</b>

<b>70. Advocacy &amp; Policy</b>				
Travel costs	-5 672	-565	-5 303	-528
Hotel costs	-3 020	-301	-5 240	-522
Food	-302	-30	0	0
Reimbursement	0	0	-4 968	-495
Gifts	-151	-15	0	0
Membership fees	-208 508	-20 773	-249 995	-24 906
Staff costs	-509 360	-50 746	0	0
Exchange profit/loss	-3 090	-308	-21 442	-2 136
<b>Total costs</b>	<b>-730 102</b>	<b>-72 737</b>	<b>-286 948</b>	<b>-28 588</b>

<b>71. IFPA Forum</b>				
Consultants	-16 658	-1 660	0	0
Other operating expenses	-85 937	-8 562	0	0
Exchange profit/loss	-309	-31	0	0
<b>Total costs</b>	<b>-102 904</b>	<b>-10 252</b>	<b>0</b>	<b>0</b>



**Costs per activity**2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
<b>75. IFPA Coalition</b>				
Translations	-21 788	-2 171	0	0
Conference costs	0	0	-6 385	-636
Consultants	-359 403	-35 806	-2 699 978	-268 989
Web	-2 614	-260	0	0
Staff costs	-251 540	-25 060	0	0
Exchange profit/loss	-1 568	-156	-3 063	-305
<b>Total costs</b>	<b>-636 913</b>	<b>-63 453</b>	<b>-2 709 426</b>	<b>-269 930</b>

<b>80. Science</b>				
Conference costs	-21 304	-2 122	-103 192	-10 281
Travel costs	0	0	-34 134	-3 401
Staff costs	-298 395	-29 728	0	0
Exchange profit/loss	0	0	-379	-38
<b>Total costs</b>	<b>-319 699</b>	<b>-31 850</b>	<b>-137 705</b>	<b>-13 719</b>

<b>85. IFPA Conference / WPPAC</b>				
Translations	-3 094	-308	0	0
Software programs	-867	-86	0	0
Freight and transport	-12 491	-1 244	0	0
Travel costs	0	0	-5 601	-558
Printing costs	-594	-59	0	0
PR-Marketing	-162 137	-16 153	-17 839	-1 777
Newsservice, PR	-1 653	-165	0	0
Entertainment	-53	-5	0	0
Gifts	-10 874	-1 083	0	0
Office material	-234	-23	0	0
Honorariums for external	-517	-52	0	0
Consultants	-65 896	-6 565	-133 135	-13 264
Other operating expenses	-223 069	-22 224	156 699	15 611
Staff costs	-636 493	-63 412	0	0
Exchange profit/loss	-2 844	-283	-124	-12
<b>Total costs</b>	<b>-1 120 816</b>	<b>-111 663</b>	<b>0</b>	<b>0</b>



**Costs per activity**2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
<b>90. Projects</b>				
Travel costs	-1 005	-100	0	0
PR-Marketing	-41 361	-4 121	0	0
Office material	-6 195	-617	0	0
Honorariums for external	-32 429	-3 231	0	0
Consultants	-2 038 663	-203 105	0	0
Other operating expenses	-279 854	-27 881	0	0
Staff costs	-167 620	-16 699	0	0
Exchange profit/loss	-32 772	-3 265	0	0
<b>Total costs</b>	<b>-2 599 900</b>	<b>-259 019</b>	<b>0</b>	<b>0</b>



**Balance sheet**2021-01-01  
2021-12-312020-01-01  
2020-12-31

<b>Bank assets and claims</b>	<b>Note</b>	SEK	EUR 10,2269	SEK	EUR 10,0375
Outstanding claims	1	3 881 730	379 561	1 427 181	142 185
Other claims		1 000	98	2 890	288
Prepaid expenses and accrued income	2	108 481	10 607	1 846 021	183 912
Cash		2 374	232	2 262	225
PayPal		0	0	1 494	149
Bank Nordea		11 429 163	1 117 559	3 809 010	379 478
<b>Total bank assets and claims</b>		<b>15 422 749</b>	<b>1 508 057</b>	<b>7 088 857</b>	<b>706 237</b>

2021-01-01  
2021-12-312020-01-01  
2020-12-31

<b>Capitals and creditors</b>	<b>Note</b>	SEK	EUR 10,2269	SEK	EUR 10,0375
Capital		3 542 451	346 386	6 083 322	606 059
Profit or loss		4 127 562	403 599	-2 540 872	-253 138
Outstanding debts		283 611	27 732	213 508	21 271
Other debts		2 468 261	241 350	1 181 542	117 713
Prepaid income	3	4 518 191	441 795	2 024 428	201 687
Accrued costs and fees paid in advance	4	482 674	47 196	126 928	12 645
<b>Total capital and creditors</b>		<b>15 422 749</b>	<b>1 508 057</b>	<b>7 088 857</b>	<b>706 237</b>



## Notes

2021-01-01  
2021-12-312020-01-01  
2020-12-31

		SEK	EUR 10,2269	SEK	EUR 10,0375
--	--	-----	----------------	-----	----------------

**Note 1 Outstanding claims**

UCB Biopharma		1 611 061	159 390	715 589	70 000
Amgen		1 143 930	114 377	0	0
AbbVie		1 089 539	110 000	0	0
Boehringer Ingelheim		37 200	3 637	0	0
Bristol Myers Squibb		0	0	709 086	70 000
Novartis Pharma		0	0	2 000	199
The ICPO "Skin and Allergic Diseases"		0	0	506	50
<b>Total</b>		<b>3 881 730</b>	<b>387 405</b>	<b>1 427 181</b>	<b>140 250</b>

**Note 2 Prepaid expenses and accrued income***Prepaid expenses*

Helioworks Gamla Stan		82 500	8 067	0	0
Europeiska ERV		7 500	733	7 500	747
Lisa Technologies		4 500	440	0	0
Scrive		2 063	202	2 063	205
Fortnox		1 865	182	1 765	176
Söderberg & Partners Insurance Consulting		1 275	125	1 250	125
Loopia		161	16	0	0
Alviks Strand kontorshotell		0	0	135 533	13 503

*Accrued income*

Accrued income AbbVie		0	0	0	0
Accrued income Pfizer		0	0	702 625	70 000
Accrued income Beohringer Ingelheim		0	0	433 274	43 166
Accrued income UCB		0	0	331 238	33 000
Accrued membership fees		0	0	7 829	780
Prepaid cost WPC		0	0	223 069	22 224
Prepaid membership fee GHC 2022		8 617	843	9 807	977
<b>Total</b>		<b>108 481</b>	<b>10 607</b>	<b>1 855 953</b>	<b>184 902</b>

## Notes

2021-01-01  
2021-12-312020-01-01  
2020-12-31

	SEK	EUR 10,2269	SEK	EUR 10,0375
--	-----	----------------	-----	----------------

**Note 3 Prepaid income**

AbbVie	1 565 642	153 091	0	0
Bristol Myers Squibb	1 351 846	132 185	1 044 297	104 040
Amgen	732 776	71 652	622 337	62 001
UCB BIOPHARMA SPRL.	554 862	54 255	357 795	35 646
Eli Lilly	262 351	25 653	0	0
Boehringer Ingelheim	50 714	4 959	0	0
<b>Total</b>	<b>4 518 191</b>	<b>441 795</b>	<b>2 024 428</b>	<b>201 687</b>

<b>Note 4 Accrued costs and fees paid in advance</b>				
Hummelklappen	40 000	3 911	92 930	9 258
Grant Thornton	0	0	23 565	2 348
Accrued reimbursement Global Skin (2019)	0	0	10 433	1 039
Creditcard costs, not yet invoiced	35 008	3 423	-9 932	-989
Accrued cost IFPA Flagships	407 666	39 862	0	0
<b>Total</b>	<b>482 674</b>	<b>47 196</b>	<b>116 997</b>	<b>11 656</b>



# Signatures

Stockholm, May 3, 2022



Hoseah Waweru  
President



Ingvar Ingvarsson  
Vice President



Leticia Lopez  
Secretary



Josef de Guzman  
Treasurer



Kathleen L. Gallant



Silvia Fernandez Barrio



David Trigos Herraes

My auditor's report has been issued on 2022-05-12

Hummelkläppen i Stockholm AB



Tommy Nilsson  
Authorized Public Accountant





Slottsbacken 8  
111 30 Stockholm, SWEDEN



ifpa-pso.com  
info@ifpa-pso.com



@psoriasisIFPA



# Verification

Transaction 09222115557468514864

## Document

### Annual Accounts 2021\_final

Main document

30 pages

Initiated on 2022-05-03 17:56:28 CEST (+0200) by Ida Mourujärvi (IM)

Finalised on 2022-05-12 14:43:59 CEST (+0200)

## Initiator

### Ida Mourujärvi (IM)

IFPA

Company reg. no. 802428-5986

ida.mourujarvi@ifpa-pso.com

+46736635251

## Signing parties

### Hoseah Waweru (HW)

IFPA

hoseah.waweru@ifpa-pso.com



Signed 2022-05-05 22:36:51 CEST (+0200)

### Ingvar Ingvarsson (II)

IFPA

ingvar.ingvarsson@ifpa-pso.com



Signed 2022-05-03 21:02:29 CEST (+0200)

### Leticia Lopez (LL)

IFPA

leticia.lopez@ifpa-pso.com



Signed 2022-05-03 17:58:27 CEST (+0200)

### Josef de Guzman (JdG)

IFPA

josef.deguzman@ifpa-pso.com



Signed 2022-05-11 04:06:01 CEST (+0200)

### Kathleen L Gallant (KLG)

IFPA

kathleen.gallant@ifpa-pso.com



Signed 2022-05-04 12:54:41 CEST (+0200)

### Silvia Fernandez Barrio (SFB)

IFPA

silviafb@ifpa-pso.com



Signed 2022-05-03 17:58:00 CEST (+0200)

### David Trigos Herraes (DTH)

IFPA

### Tommy Nilsson (TN)

Hummelkläppen i Stockholm AB



# Verification

Transaction 09222115557468514864

*david.trigos@ifpa-pso.com*



Signed 2022-05-11 18:58:34 CEST (+0200)

Company reg. no. 559105-2856

*tommy.nilsson@hummelklappen.se*



Signed 2022-05-12 14:43:59 CEST (+0200)

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: <https://scrive.com/verify>





## Translation of Auditor's Report

To the meeting of the General Assembly of its Full members of IFPA

Corporate identity number 802428-5986

### Report on the annual accounts

#### *Opinions*

I have audited the annual accounts of IFPA for the financial year 2021.

In my opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of IFPA as of 31 december 2021 and its financial performance for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts.

I therefore recommend that the general meeting of members adopts the income statement and balance sheet.

#### *Basis for Opinions*

I conducted my audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of IFPA in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

#### *Responsibilities of the Board of Directors*

The Board of Directors is responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors is also responsible for such internal control as it determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors is responsible for the assessment of the company's ability to continue as a going concern. It discloses, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is not applied if decision has been taken to discontinue the operations.

#### *Auditor's responsibility*

My objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the company's internal control relevant to my audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors .

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting in preparing the annual accounts. I also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify my opinion about the annual accounts. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

I must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. I must also inform of significant audit findings during my audit, including any significant deficiencies in internal control that I identified.

## **Report on other legal and regulatory requirements**

### ***Opinions***

In addition to my audit of the annual accounts, I have also audited the administration of the Board of Directors of IFPA for the financial year 2021 and the proposed appropriations of the company's profit or loss.

I recommend to the general meeting of members that the profit be dealt with in accordance with the proposal in the statutory administration report and that the of the Board of Directors be discharged from liability for the financial year.

### ***Basis for Opinions***

I conducted the audit in accordance with generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent IFPA in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

### ***Responsibilities of the Board of Directors***

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.

***Auditor's responsibility***

My objective concerning the audit of the administration, and thereby my opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

My objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby my opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, I exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on my professional judgment with starting point in risk and materiality. This means that I focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. I examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to my opinion concerning discharge from liability. As a basis for my opinion on the Board of Directors' proposed appropriations of the company's profit or loss I examined whether the proposal is in accordance with the Companies Act.

Stockholm 2022-05-12

  
Tommy Nilsson  
Authorized Public Accountant